曲美他嗪联合替格瑞洛治疗不稳定型心绞痛的临床疗效

Clinical Efficacy of Trimetazidine Combined with Tegrilol in the Treatment of Unstable Angina Pectoris

目的分析曲美他嗪联合替格瑞洛治疗不稳定型心绞痛的临床效果。方法我院接诊不稳定型心绞痛患者78例,时间段为2017年8月至2018年8月。研究活动实施期间依照双盲原理将患者分为对照组和观察组各39例。对照组患者使用替格瑞洛治疗,观察组在对照组治疗基础上联合曲美他嗪治疗。对比分析两组患者临床治疗效率。结果统计并比较两组患者的临床治疗效率,对照组为71.8%,低于观察组的87.2%,检验两组数据P<0.05,具有统计学意义;两组患者治疗前的心电图ST段无区别,治疗后均改善,且观察组改善效果较好,差异符合统计学意义(P<0.05);两组患者治疗前的LVEDD、LVEF指标以及心绞痛发作次数和时间各项数据无明显区别,治疗后均改善,与对照组患者相比较,观察组患者改善效果更好,检验两组患者的各项数据(P<0.05),差异符合统计学意义。结论临床治疗不稳定型心绞痛,将替格瑞洛与曲美他嗪联合应用可明显提高治疗效率,并且还能够改善患者的症状,对改善患者预后具有显著的效果,可推广应用。

Objective To analyze the clinical effect of trimetazidine combined with tiglillo in the treatment of unstable angina pectoris. Methods 78 patients with unstable angina pectoris were treated in our hospital from August 2017 to August 2018. The patients were divided into control group and observation group according to the double-blind principle during the implementation of the research activities, and 39 cases were in each group. The patients in the control group were treated with tegrillo, while the patients in the observation group were treated with trimetazidine on the basis of the treatment in the control group. The clinical treatment efficiency of the two groups was compared and analyzed. Results The clinical treatment efficiency of the two groups was 71.8% in the control group, which was lower than 87.2% in the observation group. The test data of the two groups were P <0.05, with statistical significance. There was no difference in ST segment of ECG between the two groups before treatment and after treatment, and the improvement effect of the observation group was better, with statistical significance(P<0.05). There was no significant difference in the number and time of angina pectoris attacks. After treatment, all the data were improved. Compared with the control group, the improvement effect of the observation group was better. The data of the two groups were tested P <0.05, and the difference was statistically significant. Conclusion In the clinical treatment of unstable angina pectoris, the combination of tegrilol and trimetazidine can significantly improve the treatment efficiency, improve the symptoms of patients, improve the prognosis of patients with significant effect, and can be widely applied.